Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Results From Editas CRISPR Eye Therapy Underwhelm Investors

Safety Is Reassuring But Efficacy Unclear

Executive Summary

While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.

You may also be interested in...



CRISPR Patent Ruling Lifts Editas, Disappoints Intellia and CRISPR Therapeutics

A US decision to grant a CRISPR Cas9 patent to The Broad Institute lifts Editas but adds uncertainty to the IP estate of Intellia and CRISPR Therapeutics.

Gene-Editing Companies To Watch At J.P. Morgan

Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.

SparingVision Eyes CRISPR Promise With Intellia Ocular Pact

The French biotech has managed to bag a blue-chip partner to advance its ambitions to be the leading company in the ocular genomic medicine space, getting access to Intellia's CRISPR/Cas9 technology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel